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Abstract
Introduction: Critically ill patients are predisposed to venous thromboembolism. We hypothesized that higher
doses of enoxaparin would improve thromboprophylaxis without increasing the risk of bleeding. Peak anti-factor
Xa (anti-Xa) levels of 0.1 to 0.4 IU/ml reflect adequate thromboprophylaxis for general ward patients. Studies
conducted in orthopaedic patients demonstrated a statistically significant relationship between anti-Xa levels and
wound haematoma and thrombosis. Corresponding levels for critically ill patients may well be higher, but have
never been validated in large studies.
Methods: Eighty critically ill patients weighing 50 to 90 kilograms were randomised in a double-blinded study to
receive subcutaneous (sc) enoxaparin: 40 mg once daily (QD), 30 mg twice daily (BID), 40 mg BID, or 1 mg/kg QD,
each administered for three days. Anti-Xa activity was measured at baseline, and daily at 4, 12, 16 and 24 hours
post administration. Antithrombin, fibrinogen, and platelets were measured at baseline and twice daily thereafter.
Results: Two patients were transferred prior to participation. On day 1, doses of 40 mg QD (n = 20) and 40 mg
BID (n = 19) yielded mean peak anti-Xa of 0.20 IU/ml and 0.17 IU/ml respectively. A dose of 30 mg BID (n = 20)
resulted in much lower levels (0.08 IU/ml). Patients receiving 1 mg/kg QD (n = 19) achieved near steady-state
mean peak anti-Xa levels from day 1 (0.34 IU/ml). At steady state (day 3), mean peak anti-Xa levels of 0.13 IU/ml
and 0.15 IU/ml were achieved with doses of 40 mg QD and 30 mg BID respectively. This increased significantly to
0.33 IU/ml and 0.40 IU/ml for doses of 40 mg BID and 1 mg/kg QD respectively. Thus anti-Xa response profiles
differed significantly over the three days between enoxaparin treatment groups (P <0.0001). Doses of 40 mg BID
and1 mg/kg QD enoxaparin yielded target anti-Xa levels for over 80% of the study period. There were no adverse
effects.
Conclusions: Doses of 40 mg QD enoxaparin (Europe) or 30 mg BID (North America) yield levels of anti-Xa which
may be inadequate for critically ill patients. A weight-based dose yielded the best anti-Xa levels without
bioaccumulation, and allowed the establishment of near steady-state levels from the first day of enoxaparin
administration.
Trial registration: Current Controlled Trials ISRCTN91570009.
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Introduction
The critically ill patient is especially predisposed to
venous thromboembolism (VTE), possessing many
inherent risk factors: history of VTE, renal insufficiency,
cardiac failure, trauma, sepsis, cancer, increasing age,
and obesity [1-3]. The risk of VTE is approximately 1%
per day amongst some subgroups of critically ill patients
[2]. When compared with patients who did not have
VTE, those with VTE are reported to have a longer
duration of mechanical ventilation, longer duration of
intensive care unit (ICU) or hospital stay, and higher
hospital mortality [4].
Thromboprophylaxis with agents such as enoxaparin,
a low- molecular-weight heparin (LMWH) is justified in
most ICU patients [1,5,6]. The effect of subcutaneous
(sc) enoxaparin on the coagulation cascade is thought to
be reflected by anti-factor Xa (anti-Xa) levels [7], how-
ever, this surrogate marker for efficacy has never been
validated in suitably sized studies. Normally, anti-Xa
levels peak 3 to 5 hours after dosing [8]. For sc adminis-
tration, steady-state levels are achieved after the third
dose [9].
LMWH is often employed as a safe and effective
means of prophylaxis against VTE in medical and surgi-
cal patients. Conventional target peak anti-Xa levels for
thromboprophylaxis in this population are 0.1 to 0.40
IU/ml [10]. Corresponding levels for critically ill patients
are unknown, but are likely to be higher. Levine’s study
conducted in orthopaedic patients, demonstrated a sta-
tistically significant relationship between anti-Xa levels
and the occurrence of wound haematoma and thrombo-
sis. Furthermore, regression analysis suggested anti-Xa
levels were predictive of outcome [11].
Previous studies in critically ill patients demonstrated
sub-therapeutic levels when the European standard daily
dose of 40 mg enoxaparin was administered [12,13].
VTE also tended to occur more frequently during the
ICU stay as compared to the subsequent period on the
wards. Despite ICU patients receiving LMWH, 5.1% to
15.5% developed proximal leg deep vein thrombosis in
studies conducted by Fraisse and Cook et al. [4,14].
This study aims to establish the optimal dose of enoxa-
parin for ICU patients. We hypothesised that higher
doses of enoxaparin would optimise thromboprophylaxis
without increasing the risk of bleeding in these patients.
Materials and methods
Study population
Sample population consisted of 78 consecutive eligible
patients admitted to the ICU at Odense University Hos-
pital in Denmark who were ≥18 years of age, with a
minimum stay of >24 hours. Patients weighing <50 kg
or >90 kg were excluded. Likewise, patients with coagu-
lopathy (international normalised ratio (INR) >2 times
upper limit of normal, or activated partial thromboplas-
tin time (aPTT) >2 times the upper limit of normal), or
severe thrombocytopenia (platelet count <75 × 109/L),
pregnant patients, patients requiring therapeutic antic-
oagulation, or those with contraindications to heparin,
limitation of life support or renal failure (creatinine
clearance (CrCl) <30 ml/min/1.73 m²) were deemed
ineligible. We recorded patient demographics, diagnosis
on admission and standard ICU severity of illness scores
on the day of entry into the study.
Design
A prospective randomised double-blinded study was
conducted on a mixed ICU. Patients were randomised
to receive sc enoxaparin: 40 mg once daily (QD) (con-
trol group), versus 30 mg twice daily (BID), 40 mg BID
or 1 mg/kg QD (test groups) each administered for 3
days (that is three doses total for QD regimens, and six
doses total for BID regimens). Enoxaparin was adminis-
tered to the thigh or abdomen of the study patients.
Anti-Xa activity was measured at baseline, and at 4, 12,
16 and 24 hours post administration of enoxaparin on
each day during the study period. Antithrombin (AT),
fibrinogen, and platelets were measured at the baseline,
and thereafter twice daily with the average on each day
being recorded. Patients, family members, clinicians, and
research personnel, were all unaware of study-group
assignments. Nurses, who administered the drug, were
the only party privy to the actual dose given to each
patient as it was impossible to prepare a dose of 1 mg/
kg beforehand. A fall in CrCl to <30 ml/min/1.73 m²
during the 3-day study period would result in the
patient being counted as a dropout.
The study was approved by the science ethics commit-
tee of Vejle and Funen. It was performed in accordance
with the ethical principles set forth in the Declaration of
Helsinki, and with local regulations, and monitored by
the committee for Good Clinical Practice (GCP). Writ-
ten informed consent was obtained from each patient
where possible or otherwise from the closest family
member prior to enrolment in the study.
Funding sources for this research had no role in the
design, data collection, analysis, interpretation or report-
ing of this study.
Assay methods
Samples for anti-Xa activity were analysed using a vali-
dated chromogenic assay kit (COAMATIC™ Heparin,
Chromogenix, Instrumentation Laboratory Company,
Lexington, MA, USA). A LMWH curve was utilised.
Furthermore, the anti-Xa analysis was calibrated
towards the specific LMWH type to avoid differences
that have been reported when using a standard calibra-
tion. AT and fibrinogen were analysed using STA-R
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instrument (STAGO, Triolab A/S, Brøndby, Denmark)
with dedicated reagents used according to the manufac-
turer’s instructions. Platelet counts were performed on a
Beckman Coulter LH750 (Beckman Coulter, Brea, CA,
USA).
Outcome measures
Primary endpoint was to determine the optimal enoxa-
parin dose. The optimal enoxaparin dose was defined as
that dose which would yield the highest target anti-Xa
levels, allow patients to remain within target anti-Xa
levels for >75% of the study period, and would not
cause an increase in major bleeding events. Secondary
endpoints included the identification of any correlation
between the dose of enoxaparin and (i) levels of AT,
fibrinogen, platelets, and (ii) bleeding - major and
minor.
Statistical methods
The null hypothesis was that there was no difference in
peak anti-Xa levels between the groups. On the basis of
data from previous studies, this study was designed with
80% power to detect a 30% absolute difference in anti-
Xa levels between the groups, giving a total sample size
of 80 patients. All baseline demographic values were
compared using one-way ANOVA (numerical data) or
chi-squared test (categorical data). Statements of statisti-
cal significance are based on a two-tailed test with a
level of 0.05. Individual change over time is pursued by
repeated effects modelling, which allows for correlation
among measurements taken on the same patient over
time. Our initial model used APACHE II, SOFA, creati-
nine clearance, weight, age, gender, time, treatment allo-
cation and an interaction between treatment and time
as possible predictors for the anti-Xa levels. Subse-
quently, model simplifications were based on likelihood
ratio tests. Patients were analysed in the group to which
they were randomised, according to the intention-to-
treat principle.
Results
Study population
A total of 78 ICU patients were enrolled in the study
between January 2011 and September 2012. The consent
rate for participation was approximately 80%. The Con-
sort diagram [15] shows patient disposition (Figure 1).
During this period, we excluded 690 patients and rando-
mised 80 patients. The most frequent reasons for exclu-
sion were: 1) extremes of weight (25%); 2) creatinine
clearance <30 ml/min/1.73m2 (24%); 3) haemorrhage on
ICU admission (21%); 4) thrombocytopenia or coagulo-
pathy (14%); 5) therapeutic anticoagulation (12%).
The majority of patients were admitted with respira-
tory failure due to pneumonia or exacerbation of
chronic obstructive pulmonary disease (COPD) (73%).
Other reasons for admission included: sepsis, intra-
abdominal abscess, pancreatitis, and multiple trauma. At
baseline, patients did not differ significantly between the
control group (40 mg QD), and the three test groups.
Patients had normal renal function and were moderately
ill as assessed by severity of illness scores (Table 1).
Primary results
Unblinding occurred on 1 October 2012. For patients
with 1 mg/kg QD the mean administered dose of enoxa-
parin was 75 mg. Repeated measures modelling revealed
that anti-Xa levels differed in a linear fashion with the
dose of enoxaparin administered, and the time at which
the blood samples were drawn. On the first day of enox-
aparin administration, doses of 40 mg QD and 40 mg
BID yielded similar mean peak anti-Xa of 0.20 IU/ml
and 0.17 IU/ml respectively, while a dose of 30 mg BID
resulted in much lower levels of anti-Xa (0.08 IU/ml).
Patients receiving 1 mg/kg QD enoxaparin achieved
near steady-state levels from day 1 of administration
with mean peak anti-Xa levels of 0.34 IU/ml (Figure 2).
Steady-state anti-Xa was achieved for all doses of enoxa-
parin at day 3. At steady state, mean peak anti-Xa levels
of 0.13 IU/ml and 0.15 IU/ml were achieved with doses
of 40 mg QD and 30 mg BID respectively. This
increased significantly to 0.33 IU/ml and 0.40 IU/ml for
doses of 40 mg BID and 1 mg/kg QD enoxaparin
respectively. The anti-Xa response profiles were thus
significantly different over the 3 days between the four
treatment allocation groups (P <0.0001). Patients main-
tained anti-Xa levels within a target range of 0.1 to
0.4 IU/ml for: 33.3% (40 mg QD), 41.7% (30 mg BID),
83% (1 mg/kg QD) and 91.7% (40 mg BID) of the study
period (Figure 3). There were no adverse effects.
Secondary results
There was no significant difference in the AT, platelet
count, or fibrinogen between the four groups (Table 2).
There was no significant change from baseline in these
coagulation parameters within each group over the
72-hour study period (Table 3).
Adverse events
Four patients died during the course of the study - one
patient from each group. These deaths were not a direct
complication of enoxaparin use. All patients who died
did so after withdrawal of active therapy. They had the
following diagnoses: pneumocystis pneumonia, intersti-
tial lung disease, lung metastases complicated by pneu-
monia and severe sepsis due intra-abdominal infection.
There were no episodes of bleeding. One patient
experienced a fall in platelet count to half the baseline
value within 2 days of starting the trial on 40 mg
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      791 patients: ≥18 years of age & 
          assessed for eligibility 
        101 patients judged to be eligible 
   80 patients included                      
 
21 patients (or their 
relatives) declined 
2 patients were transferred 
before they could participate 
              78 patients randomised 
 
Enoxaparin  
40 mg QD   
 N= 20                  
Enoxaparin  
30 mg BID 
 N= 20                  
Enoxaparin  
40 mg BID   
 N= 19                  
Enoxaparin  
1 mg/kg QD   
 N= 19                
690 patients were excluded: 
174 - outside weight limit 
165 – renal failure 
143 – haemorrhage on ICU admission 
99 – low platelet count/coagulopathy 
86 – therapeutic anticoagulation 
23 – limitation of life support etc… 
Figure 1 Consort diagram.
Table 1 Clinical characteristics of the study population.
Enoxaparin dose 40 mg QD
(N = 20)
30 mg BID
(N = 20)
40 mg BID
(N = 19)
1 mg/kg QD
(N = 19)
P value
Sex (male:female) 12:8 14:6 8:11 9:10 0.31
Age (years) 59.9 ± 10.8 65.8 ± 14.7 65.6 ± 15.8 63.5 ± 13.8 0.44
Weight (kg) 69.6 ± 12.2 68.5 ± 10.9 67.8 ± 11.8 74.8 ± 9.4 0.71
SAPS II 40.2 ± 11.8 41.6 ± 10.4 44.9 ± 14.8 45.2 ± 16.6 0.18
APACHE II 20.7 ± 6.5 21.5 ± 6.0 22.6 ± 6.1 23.7 ± 7.4 0.80
SOFA 4.7 ± 1.7 4.6 ± 1.8 4.7 ± 1.4 4.4 ± 1.5 0.73
Creatinine clearance (ml/min) 83 ± 14.2 83 ± 12.8 80 ± 18.0 77.8 ± 18.4 0.33
Medical:surgical 17:3 19:1 16:3 17:2 0.73
Plus-minus values are means ± standard deviation (SD). QD, once daily: BID, twice daily; N, number; SAPS II, Simplified Acute Physiology Score II: APACHE II, Acute
Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment score.
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enoxaparin QD sc. However, this patient was also receiv-
ing azathioprine due to idiopathic lung fibrosis. There
were no cases of heparin-induced thrombocytopenia.
Discussion
In the present study, enoxaparin 1 mg/kg QD resulted
in the highest target anti-Xa levels, and allowed patients
to remain within target anti-Xa levels for >80% of the
study period. There was no evidence of bioaccumulation
or bleeding episodes.
Critically ill patients are predisposed to VTE. The 9th
American College of Chest Physicians’ guidelines and
the latest edition of Surviving Sepsis campaign guide-
lines recommend the use of LMWH or unfractionated
heparin, to combat VTE in critically ill patients.
Mechanical thromboprophylaxis with intermittent com-
pression devices or graduated compression stockings are
recommended in patients with a high bleeding risk or
contraindications to heparin [6,16].
Anti-Xa levels are used to judge the degree of thrombo-
prophylaxis. Among orthopaedic patients, one study was
able to demonstrate that anti-Xa levels were predictive of
outcome[11]. This surrogate marker for efficacy has never
been validated in suitably sized studies, and the optimal
levels for critically ill patients are not known.
In ICUs across Europe, a standard dose of 40 mg QD
enoxaparin sc is often employed for thromboprophylaxis
[17]. A dose of 30 mg BID sc enoxaparin is thought to
be equipotent, and is used widely throughout North
America. Riha et al. prospectively followed 63 surgical
patients receiving a dose of either 30 mg BID or 40 mg
QD enoxaparin. They found that a dose of 40 mg once
daily resulted in significantly higher peak anti-Xa levels
and a correspondingly lower incidence of VTE com-
pared with 30 mg twice daily [18].
Our study showed that while a dose of 30 mg BID
resulted in lower levels of anti-Xa on the first day of
administration, at steady state this dose yielded mean
anti-Xa levels that were nearly indistinguishable from
that of 40 mg QD enoxaparin. The discrepancy in these
findings may be due to the diverse patient population
on our ICU which houses both medical and surgical
patients.
Patients receiving 1 mg/kg QD enoxaparin achieved
near steady-state anti-Xa levels from day 1 of adminis-
tration, and this could be advantageous in a population
where the occurrence of VTE can have grave conse-
quences. Peak anti-Xa levels did not surpass maximum
acceptable anti-Xa levels of 0.4 IU/ml for doses of
40 mg BID and 1 mg/kg QD enoxaparin. Higher anti-
Xa levels are attractive in critically ill patients as they
may confer better thromboprophylaxis. With an earlier
study, we established that patients were more likely to
maintain anti-Xa levels within the target therapeutic
range for longer periods of time when given higher
doses of enoxaparin [13]. Similar results were obtained
with the present study. Here, doses of 1 mg/kg QD and
40 mg BID yielded target range anti-Xa levels for over
80% of the study period. However the latter dose
resulted in target range anti-Xa levels even at trough
measurements, and this accounts for the higher percen-
tage yield. This may also give rise to bioaccumulation.
ICU patients have an apparent heparin resistance
thought to be due to physiological mechanisms, or use
of pharmacological agents for example vasopressors
(may impair absorption of sc LMWH through adrener-
gic-mediated vasoconstriction of peripheral blood ves-
sels), or the presence of multiple organ dysfunction
(may alter drug metabolism, distribution, and binding to
albumin and acute phase proteins) [10,19,20]. Thus
other possible explanations for the difference in anti-Xa
levels could be: differences in volumes of distribution or
levels of hypoproteinemia or dose of vasopressor, as well
as the presence/absence of sc oedema. Renal function
Table 2 Coagulation parameters at baseline.
Parameter Enoxaparin
40 mg QD
Enoxaparin
30 mg BID
Enoxaparin
40 mg BID
Enoxaparin
1 mg/kg QD
P value
Platelets (×109/L) 285 ± 107 238 ± 112 223 ± 95 276 ± 121 0.78
AT (%) 87 ± 24 75 ± 20 89 ± 23 91 ± 23 0.90
Fibrinogen (mg/dL) 588.4 ± 194 527.2 ± 167 612.2 ± 180 547.6 ± 150 0.74
Data are means ± standard deviation (SD). QD, once daily; BID, twice daily; AT, antithrombin.
Table 3 Coagulation parameters at 72 hours.
Parameter Enoxaparin
40 mg QD
Enoxaparin
30 mg BID
Enoxaparin
40 mg BID
Enoxaparin
1 mg/kg QD
P value
Platelets (×109/L) 298 ± 108 299 ± 155 258 ± 129 276 ± 132 0.62
AT (%) 88 ± 35 85 ± 17 85 ± 33 87 ± 25 0.07
Fibrinogen (mg/dL) 571.4 ± 146 506.8 ± 180 612.2 ± 207 517 ± 170 0.69
Data are means ± standard deviation (SD). QD, once daily; BID, twice daily; AT, antithrombin.
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and antithrombin levels were equivalent in all four
groups and so are not thought to have contributed.
No significant change from baseline occurred in AT,
platelet count, and fibrinogen, irrespective of the dose of
enoxaparin. These findings are consistent with other
studies, which found no change in these haemostatic
parameters with LMWH use [12,13,19].
One patient experienced thrombocytopenia due to
concomitant azathioprine administration. Thrombocyto-
penia in ICU patients may occur because of drug
administration, use of dialysis, increased platelet con-
sumption, or decreased platelet production. Thrombocy-
topenia in the critically ill may also be a marker of
severe physiological stress [21].
No bleeding episodes occurred with the present study.
This was not surprising, given the mean CrCl of 80 ml/
min, the exclusion of patients with coagulopathy and
the relatively short study period. Major bleeding
occurred in 5.5% of ICU patients assigned to receive
thromboprophylaxis with LMWH in a recent study con-
ducted by Cook et al. [4]. Many critically ill patients
experience bleeding episodes, the majority of which will
be minor. Major or fatal bleeding in the ICU is thought
to be associated with prolonged global tests of coagula-
tion and low platelet counts rather than with the use of
prophylactic anticoagulants or antiplatelet agents [22].
Such patients were excluded from the present study.
Periodic monitoring of anti-Xa levels is recommended
in special populations, for example, pregnant patients,
children, patients with acute kidney injury (AKI), or
those at extremes of body weight [23].
With only 3 days of observation, our study was not
designed to detect VTE - a clear limitation. Other limita-
tions include single-centre experience, and not recording
the presence/absence of oedema. The study was also con-
fined to patients who weighed between 50 and 90 kg to
allow for comparison with our earlier study. The use of
concomitant vasopressor was not recorded, and may have
influenced the results. Dörffler-Melly’s study [20] from
2002 showed impaired absorption of sc LMWH through
adrenergic-mediated vasoconstriction, however, in a later
study conducted by Priglinger [12] in 2003, no such corre-
lation was found between the anti-Xa activity and the dose
of norepinephrine.
Strengths of the present study include daily screening
for consecutive eligible patients thereby minimising the
potential for selection bias. Also the validity of our
results is ensured as the dependent variable (anti-Xa
level) was not subject to interpretation bias. The four
study groups were well matched, and the results are
highly significant, however they will have to be evaluated
in a larger trial.
Our findings cannot be extrapolated as proof that ICU
patients receiving 1 mg/kg QD are better protected than
those receiving a standard dose of 40 mg QD, as anti-
Xa activity is only a surrogate parameter. This could
only be proven with adequately powered clinical trials.
It remains to be established whether these results
obtained with enoxaparin can be generalised to other
LMWHs.
Conclusions
Our study illustrates the inadequacy of the current stan-
dard doses of enoxaparin 40 mg QD (Europe) or 30 mg
BID (North America) to yield target therapeutic range
anti-Xa in critically ill patients weighing 50 to 90 kg.
It also demonstrates a clear relationship between anti-
Xa levels and the dose of enoxaparin, with higher doses
yielding better peak anti-Xa levels. Higher doses also
allowed the establishment of near steady-state levels
from the first day of enoxaparin administration.
The dual risks of VTE and bleeding, coupled with an
overwhelming tendency to exclude patients with AKI
continues to complicate the establishment of a strategy
for thromboprophylaxis in this patient population. A
weight-based dose yielded the best anti-Xa levels with-
out an accompanying risk of bioaccumulation, and may
thus be more appropriate, convenient and effective. A
new study using 1 mg/kg QD enoxaparin has recently
been approved by the Danish Ministry of Health. It will
be conducted in AKI patients upon commencing contin-
uous veno-venous haemofiltration, and will have clinical
endpoints such as the occurrence of VTE and bleeding,
length of stay, number of ventilator-free days, and
mortality.
Key messages
• doses of 40 mg QD and 30 mg BID enoxaparin yield
sub-therapeutic levels of anti-Xa in critically ill patients.
• a dose of 1 mg/kg QD enoxaparin is more likely to
achieve a target anti-Xa range of 0.1 to 0.4 U/ml.
• thromboprophylactic studies with clinical endpoints
should be vigorously pursued.
Abbreviations
AKI: acute kidney injury; anti-Xa: anti-factor Xa; APACHE II: Acute Physiology
and Chronic Health Evaluation; aPTT: activated partial thromboplastin time;
AT: antithrombin; BID: twice daily; COPD: chronic obstructive pulmonary
disease; CrCl: creatinine clearance; GCP: Good Clinical Practice; ICU: intensive
care unit; INR: international normalised ratio; LMWH: low- molecular-weight
heparin; N: number; QD: once daily; SAPS II: Simplified Acute Physiology
Score II; sc: subcutaneous; SD: standard deviation; SOFA: Sequential Organ
Failure Assessment score; VTE: venous thromboembolism.
Authors’ contributions
PT conceived the research, revised the manuscript, and secured funding for
the project. SR designed the study, enrolled and followed up patients,
interpreted the results, performed the statistical analysis, and drafted the
manuscript. AZ and ULL enrolled and followed up patients and revised the
manuscript. CE assisted with the statistical analysis and revised the
manuscript. MN assisted with the interpretation of the results and revised
Robinson et al. Critical Care 2013, 17:R75
http://ccforum.com/content/17/2/R75
Page 7 of 8
the manuscript. BR carried out the chromogenic assays and revised the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
Funding was provided through generous grants received from The Danish
Society of Anaesthesiology and Intensive Care Medicine’s research initiative.
The authors are also indebted to Annie Sten, and the nursing staff of
Odense University Hospital’s ICU for their invaluable assistance throughout
the project.
Author details
1Department of Anaesthesia and Intensive Care, Odense University Hospital
(OUH), Sdr. Boulevard 29. Odense C, DK 5000, Denmark. 2Department of
Biostatistics, University of Southern Denmark, J.B. Winsløws Vej 9B, 2. Odense
C, DK 5000, Denmark. 3Department of Clinical Biochemistry and
Pharmacology, OUH, Sdr. Boulevard 29. Odense C, DK 5000, Denmark.
Received: 11 December 2012 Revised: 8 March 2013
Accepted: 18 April 2013 Published: 19 April 2013
References
1. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR,
Colwell CW, American College of Chest Physicians: Prevention of venous
thromboembolism: American College of Chest Physicians Evidence-
Based Clinical Practice Guidelines (8th Edition). Chest 2008,
133:381S-453S.
2. Shorr AF, Williams MD: Venous thromboembolism in critically ill patients.
Observations from a randomized trial in sepsis. Thromb Haemost 2009,
101:139-144.
3. Cook DJ, Crowther MA: Thromboprophylaxis in the intensive care unit:
focus on medical-surgical patients. Crit Care Med 2010, 38:S76-S82.
4. PROTECT Investigators for the Canadian Critical Care Trials Group and the
Australian and New Zealand Intensive Care Society Clinical Trials Group,
Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE,
Zytaruk N, Crowther M, Geerts W, Cooper DJ, Vallance S, Qushmaq I,
Rocha M, Berwanger O, Vlahakis NE: Dalteparin versus unfractionated
heparin in critically ill patients. N Engl J Med 2011, 364:1305-1314.
5. Chan CM, Shorr AF: Venous thromboembolic disease in the intensive
care unit. Semin Respir Crit Care Med 2010, 31:39-46.
6. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ,
Balekian AA, Klein RC, Le H, Schulman S, Murad MH, American College of
Chest Physicians: Prevention of VTE in nonsurgical patients:
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:
American College of Chest Physicians Evidence-Based Clinical Practice
Guidelines. Chest 2012, 141:e195S-e226S.
7. Crowther M, Lim W: Low molecular weight heparin and bleeding in
patients with chronic renal failure. Curr Opin Pulm Med 2007, 13:409-413.
8. Noble S, Peters DH, Goa KL: Enoxaparin. A reappraisal of its
pharmacology and clinical applications in the prevention and treatment
of thromboembolic disease. Drugs 1995, 49:388-410.
9. Sanderink GJ, Le Liboux A, Jariwala N, Harding N, Ozoux ML, Shukla U,
Montay G, Boutouyrie B, Miro A: The pharmacokinetics and
pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol
Ther 2002, 72:308-318.
10. Rabbat CG, Cook DJ, Crowther MA, McDonald E, Clarke F, Meade MO,
Lee KA, Cook RJ: Dalteparin thromboprophylaxis for critically ill medical-
surgical patients with renal insufficiency. J Crit Care 2005, 20:357-363.
11. Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M: The
relationship between anti-factor Xa level and clinical outcome in
patients receiving enoxaparine low molecular weight heparin to prevent
deep vein thrombosis after hip replacement. Thromb Haemost 1989,
62:940-944.
12. Priglinger U, Delle Karth G, Geppert A, Joukhadar C, Graf S, Berger R,
Hülsmann M, Spitzauer S, Pabinger I, Heinz G: Prophylactic anticoagulation
with enoxaparin: Is the subcutaneous route appropriate in the critically
ill? Crit Care Med 2003, 31:1405-1409.
13. Robinson S, Zincuk A, Strom T, Larsen TB, Rasmussen B, Toft P: Enoxaparin,
effective dosage for intensive care patients: double-blinded, randomised
clinical trial. Crit Care 2010, 14:R41.
14. Fraisse F, Holzapfel L, Couland JM, Simonneau G, Bedock B, Feissel M,
Herbecq P, Pordes R, Poussel JF, Roux L: Nadroparin in the prevention of
deep vein thrombosis in acute decompensated COPD. The Association
of Non-University Affiliated Intensive Care Specialist Physicians of
France. Am J Respir Crit Care Med 2000, 161:1109-1114.
15. Moher D, Schulz KF, Altman DG: The CONSORT statement: revised
recommendations for improving the quality of reports of parallel-group
randomised trials. Lancet 2001, 357:1191-1194.
16. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM,
Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME,
Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS,
Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R,
Surviving Sepsis Campaign Guidelines Committee including The Pediatric
Subgroup: Surviving sepsis campaign: international guidelines for
management of severe sepsis and septic shock, 2012. Intensive Care Med
2013, 39:165-228.
17. Horlocker TT, Heit JA: Low molecular weight heparin: biochemistry,
pharmacology, perioperative prophylaxis regimens, and guidelines for
regional anesthetic management. Anesth Analg 1997, 85:874-885.
18. Riha GM, Van PY, Differding JA, Schreiber MA: Incidence of deep vein
thrombosis is increased with 30 mg twice daily dosing of enoxaparin
compared with 40 mg daily. Am J Surg 2012, 203:598-602.
19. Mayr AJ, Dünser M, Jochberger S, Fries D, Klingler A, Joannidis M,
Hasibeder W, Schobersberger W: Antifactor Xa activity in intensive care
patients receiving thromboembolic prophylaxis with standard doses of
enoxaparin. Thromb Res 2002, 105:201-204.
20. Dörffler-Melly J, de Jonge E, Pont AC, Meijers J, Vroom MB, Büller HR,
Levi M: Bioavailability of subcutaneous low-molecular-weight heparin to
patients on vasopressors. Lancet 2002, 359:849-850.
21. Crowther MA, Cook DJ, Meade MO, Griffith LE, Guyatt GH, Arnold DM,
Rabbat CG, Geerts WH, Warkentin TE: Thrombocytopenia in medical-
surgical critically ill patients: prevalence, incidence, and risk factors. J Crit
Care 2005, 20:348-353.
22. Arnold DM, Donahoe L, Clarke FJ, Tkaczyk AJ, Heels-Ansdell D, Zytaruk N,
Cook R, Webert KE, McDonald E, Cook DJ: Bleeding during critical illness:
a prospective cohort study using a new measurement tool. Clin Invest
Med 2007, 30:E93-E102.
23. Duplaga BA, Rivers CW, Nutescu E: Dosing and monitoring of low-
molecular-weight heparins in special populations. Pharmacotherapy 2001,
21:218-234.
doi:10.1186/cc12684
Cite this article as: Robinson et al.: A comparative study of varying doses
of enoxaparin for thromboprophylaxis in critically ill patients: a double-
blinded, randomised controlled trial. Critical Care 2013 17:R75.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Robinson et al. Critical Care 2013, 17:R75
http://ccforum.com/content/17/2/R75
Page 8 of 8
